0001493152-25-003670.txt : 20250124 0001493152-25-003670.hdr.sgml : 20250124 20250124212943 ACCESSION NUMBER: 0001493152-25-003670 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250122 FILED AS OF DATE: 20250124 DATE AS OF CHANGE: 20250124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Opaleye Management Inc. CENTRAL INDEX KEY: 0001595855 ORGANIZATION NAME: STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35814 FILM NUMBER: 25555570 BUSINESS ADDRESS: STREET 1: ONE BOSTON PLACE STREET 2: SUITE 2600 CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 617-904-9195 MAIL ADDRESS: STREET 1: ONE BOSTON PLACE STREET 2: SUITE 2600 CITY: BOSTON STATE: MA ZIP: 02108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HARROW, INC. CENTRAL INDEX KEY: 0001360214 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 450567010 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 102 WOODMONT BLVD STREET 2: SUITE 610 CITY: NASHVILLE STATE: TN ZIP: 37215 BUSINESS PHONE: 615.733.4731 MAIL ADDRESS: STREET 1: 102 WOODMONT BLVD STREET 2: SUITE 610 CITY: NASHVILLE STATE: TN ZIP: 37215 FORMER COMPANY: FORMER CONFORMED NAME: HARROW HEALTH, INC. DATE OF NAME CHANGE: 20181228 FORMER COMPANY: FORMER CONFORMED NAME: Imprimis Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20120301 FORMER COMPANY: FORMER CONFORMED NAME: TRANSDEL PHARMACEUTICALS INC DATE OF NAME CHANGE: 20070912 4 1 ownership.xml X0508 4 2025-01-22 0 0001360214 HARROW, INC. HROW 0001595855 Opaleye Management Inc. ONE BOSTON PLACE, 26TH FLOOR BOSTON MA 02108 0 0 1 0 0 Common Stock, par value $0.001 per share 2025-01-22 4 S 0 20000 35.5907 D 155000 I By Managed Account Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.595-$36.64 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Opaleye Management Inc., By: /s/ James Silverman, President 2025-01-24